Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for
community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve
outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple
treatment modalities in the event of a respiratory pandemic resulting in critical illness.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Phase:
Phase 4
Details
Lead Sponsor:
MJM Bonten UMC Utrecht
Collaborators:
Australian and New Zealand Intensive Care Research Centre Berry Consultants Global Coalition for Adaptive Research Medical Research Institute of New Zealand Unity Health University of Pittsburgh Medical Center